memantine has been researched along with Clasp-Knife Spasticity in 6 studies
Excerpt | Relevance | Reference |
---|---|---|
"We report the results of a single center randomized, double-blind, placebo-controlled, parallel group trial of memantine in adults with multiple sclerosis and spasticity conducted over 12 weeks." | 9.14 | A randomized trial of memantine as treatment for spasticity in multiple sclerosis. ( Goodman, AD; McDermott, MP; Mehta, LR; Schwid, SR, 2010) |
"We report the results of a single center randomized, double-blind, placebo-controlled, parallel group trial of memantine in adults with multiple sclerosis and spasticity conducted over 12 weeks." | 5.14 | A randomized trial of memantine as treatment for spasticity in multiple sclerosis. ( Goodman, AD; McDermott, MP; Mehta, LR; Schwid, SR, 2010) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (33.33) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 1 (16.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kasatkin, DS | 1 |
Mehta, LR | 1 |
McDermott, MP | 1 |
Goodman, AD | 1 |
Schwid, SR | 1 |
Grossmann, W | 1 |
Schütz, W | 1 |
Rösche, J | 1 |
Schwarz, M | 1 |
Block, F | 1 |
Sontag, KH | 1 |
Mundinger, F | 1 |
Milios, E | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Memantine for Spasticity in MS Patients[NCT00638027] | Phase 4 | 21 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"9-Hole Peg Test (9-HPT) is a quantitative measure of upper extremity function. Timed 25-Foot Walk (T 25 FW) is a quantitative measure of lower extremity function. The patient is instructed to walk 25 feet as quickly as possible, but safely.~Paced Auditory Serial Addition Test-3 seconds (PASAT-3) is a measure of cognitive function that assesses auditory information processing speed and flexibility, as well as calculation ability.~The MSFC is based on the concept that scores for these 3 dimensions-arm, leg, and cognitive function are combined to create a single score that can be used to detect change over time in a group of MS patients. This is done by creating Z-scores for each component of the MSFC. Implicit in this approach is the idea that patients who deteriorate or improve on all 3 component measures will have an overall larger change than patients who change on only 1 of the 3 measures. The MSFC score was transformed to z-scores, with higher scores indicating better outcome." (NCT00638027)
Timeframe: Baseline, Week 12
Intervention | Z score (Mean) |
---|---|
Memantine | 0.02 |
Placebo | -0.04 |
"spasticity scale score: the most common used tool to measure the degree of spasticity of the lower extremities.~Score: Degree of Muscle Tone 0: no increase in tone~slight increase in tone 1+: slight increase in tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the range of motion.~more marked increase in muscle tone through most of the range of movement, but affected part(s) easily moved.~considerable increase in muscle tone, passive movement difficult.~affected part(s) rigid in flexion or extension." (NCT00638027)
Timeframe: Baseline and 12 weeks
Intervention | units on a scale (Mean) |
---|---|
Memantine | -1.55 |
Placebo | -1.00 |
"Multiple Sclerosis Spacticy Scale (MSSS-88) is a patient reported questionnaire rating scale to quantify the perspectives of the impact of spasticity on people with multiple sclerosis.~Scoring: Individual items are scored on a 4 point Likert scale: 1 (Not bothered at all), 2 (a little bothered), 3 (moderately bothered), 4 (extremely bothered).This questionnaire asks how bothered you have been by your spasticity in the past two weeks. By spasticity we mean muscle stiffness and spasms.The MSSS-88 is a reliable and valid, patient-based, interval-level measure of the impact of spasticity in multiple sclerosis. Scores were summed, without weighting or standardization, to generate ordinal-level total scores just as any other Likert-type scale. Missing responses to items can be replaced with the mean score of the items completed (person-specific item mean score) provided that 50% or more of the items in a scale have been completed. The range is 8-32 and higher scores mean poorer outcome." (NCT00638027)
Timeframe: baseline, 12 weeks
Intervention | units on a scale (Mean) |
---|---|
Memantine | -5.55 |
Placebo | -3.33 |
1 trial available for memantine and Clasp-Knife Spasticity
Article | Year |
---|---|
A randomized trial of memantine as treatment for spasticity in multiple sclerosis.
Topics: Adult; Disability Evaluation; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans | 2010 |
5 other studies available for memantine and Clasp-Knife Spasticity
Article | Year |
---|---|
[Pathogenetic therapy of spasticity].
Topics: Adult; Aged; Animals; Cerebral Palsy; Child; Controlled Clinical Trials as Topic; Dantrolene; Diseas | 2008 |
[Memantine and neurogenic bladder disorders within the bounds of spastic conditions].
Topics: Adult; Aged; Amantadine; Electromyography; Female; Humans; Male; Memantine; Middle Aged; Muscle Spas | 1982 |
Treatment of spasticity.
Topics: Acetates; Amines; Aminopyridines; Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Clonidine; Cy | 2002 |
N-methyl-D-aspartate (NMDA)-mediated muscle relaxant action of memantine in rats.
Topics: Animals; Electromyography; Female; Male; Memantine; Muscle Relaxation; Muscle Spasticity; N-Methylas | 1992 |
[Experiences with memantine in the treatment of severe spastic and extrapyramidal movement disorders in combination with stereotaxic surgery].
Topics: Adolescent; Adult; Aged; Amantadine; Athetosis; Basal Ganglia Diseases; Cerebral Palsy; Child; Chore | 1985 |